

**Supplementary Table 4.** Changes in efficacy variables by treatment subgroup at week 12

Variable	Teneligliptin		Placebo	
	Teneligliptin (n=11)	Teneligliptin+metformin (n=23)	Placebo (n=9)	Placebo+metformin (n=21)
HbA1c, %				
Baseline	7.66±0.74	7.42±0.53	7.92±0.72	7.56±0.62
Change at week 12 <sup>a</sup>	-0.87±0.19	-0.81±0.15	-0.05±0.22	-0.08±0.15
FPG, mg/dL				
Baseline	144.3±18.8	131.8±21.7	145.7±22.5	141.9±28.5
Change at week 12 <sup>a</sup>	-18.9±6.3	-13.7±4.9	1.5±7.1	-2.5±4.9

Values are presented as mean ± standard deviation or least-squares mean ± standard error.

HbA1c, glycosylated hemoglobin; FPG, fasting blood glucose.

<sup>a</sup>Least-squares mean ± standard error.